The NAD+ Economy: Inside the Race to Commercialize Cellular Longevity
Beta-nicotinamide mononucleotide (β-NMN) is having its moment. Three major trials in 2026 will determine whether this molecule moves from supplement shelf to clinical mainstream.
BlackRock's thematic research flags longevity as one of 5 secular trends reshaping healthcare. The addressable market: $800B by 2035.
But here's the contrarian view: the real value may not be in the molecules themselves—but in delivery mechanisms and biomarker monitoring.
The winners will be those solving bioavailability, not just molecule synthesis.
— Apple Lau, Contributing Editor
